Bronchoscopic Intratumoral injection of Tranexamic Acid for prevention of excessive bleeding during multiple forceps biopsy procedure

Bronchoscopic intratumoral injection of tranexamic acid for prevention of excessive bleeding during multiple forceps biopsy procedure in patients with endobronchial tumors with a high risk of bleeding

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN23323895

Enrollment

Registered

2013-11-08

Start date

2009-10-13

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer Cancer Malignant neoplasm of bronchus and lung

Interventions

Transamine ampoule (tranexamic acid) is injected through a 22-gauge Wang cytology needle into the lesion in fractional amounts at various points in nominal doses from 250 to 500 mg. All patients are

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Written informed consent 2. Adults aged over 18 years, either sex 3. Patients suspected of lung cancer by signs, symptoms, chest radiograph and computed tomography and/or fluorodeoxyglucose positron emission tomography findings

Exclusion criteria

Exclusion criteria: 1. Unfit to undergo a bronchoscopy 2. History or risk of thrombosis, active thromboembolic disease, subarachnoid hemorrhage 3. A known or suspected bleeding disorder 4. Thrombocytopenia 5. Uremia 6. Disturbances of color vision

Design outcomes

Primary

Measure	Time frame
Performance of multiple forceps biopsy procedure in patients with endobronchial tumors without producing active bleeding	—

Secondary

Measure	Time frame
1. Adverse effects during and after IIT 2. Cost-effectiveness of the IIT	—

Countries

Turkey

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 21, 2026